ENGLISH ABSTRACT
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

[Treatment of ANCA associated systemic necrotizing vasculitides].

Vasculitides associated with antineutrophil cytoplasmic antibodies (ANCA) mainly affect small vessels. These disorders comprise crescentic glomerulonephritis, Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome. Treatment of ANCA-associated vasculitides should be adapted to the type and severity of clinical manifestations, and to certain patient characteristics. Corticosteroids and immunosuppressants are compulsory in Wegener's granulomatosis, but steroids alone can be prescribed to patients with Churg-Strauss syndrome and microscopic polyangiitis without factors of poor prognosis. New biotherapies are showing promise in selected patients but need to be evaluated in the long term. Immunosuppressant and steroid dose reductions, and widespread use of pulse cyclophosphamide instead of oral treatment, have improved patient outcome. Remission is currently obtained in more than 90% of cases but relapses are frequent: for example, more than 50% of Wegener's patients relapse three years after remission. New strategies are needed to prevent relapses and to limit adverse drug effects.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app